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ABSTRACT
Objective: A 21-year-old man who presented with a 17-month history of unremitting anxiety associated with panic attacks 
was studied.
Result: The anxiety with panic attacks did not abate with escitalopram 15 mg nocte and alprazolam 0.5 mg tds. At month 3, 
the patient reported low mood and unexplained sexual arousal in addition to the unremitting anxiety symptoms. His condition 
fairly improved with addition of quetiapine. At month 17, transition to psychotic disorder occurred when the patient experi-
enced hallucinations for the first time. Quetiapine was increased to 500 mg nocte and the anxiety symptoms improved tremen-
dously before he relapsed 6 months later due to poor compliance.
Conclusion: Unremitting anxiety with depression can be a dominant feature during the schizophrenia prodrome. Atypical 
antipsychotic quetiapine is an interesting treatment option due to its status as approved adjunctive treatment for major depres-
sive disorder and promising efficacy for generalized anxiety disorder.
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Schizophrenia is chronic debilitating mental disorder that involves 
tremendous direct and indirect costs to the patients, their families and 
society. Interest in identification of prodromal phase of schizophrenia is 
increasing as the focus now shifts to the prevention of mental illnesses. 
Recent findings in patients with an emerging psychotic disorder suggest 
that schizophrenia may present with significant neurotic symptoms. 
Meta-analysis of 1683 high-risk subjects showed that baseline preva-
lence of comorbid depressive and anxiety disorders is respectively 41% 
and 15%1). In a local study, 55% of the subjects with sub-threshold 
attenuated psychotic symptoms (APS) had associated depression and/or 
anxiety2). Here, we report a case of schizophrenia presenting with prom-
inent unremitting anxiety symptoms.
CASE 
The patient was a 21-year-old student living with his mother and 
elder sister. He was referred to the psychiatry clinic via the family phy-
sician, having presented with unremitting anxiety associated with panic 
attacks. The first episode was 2 month before which was described as 
sudden onset of burning epigastric pain which was treated as gastritis. 
Another episode occurred while he was talking with his friend during 
Friday prayer. The panic attack which lasted about half an hour was 
characterized by a discreet episode of sudden onset of palpitation, short-
ness of breath, chest tightness, numbness of extremities, burning epigas-
tric pain and sense of impending blackout. He was also worried that he 
might be having a brain tumor or other neurological conditions. He 
searched for information regarding his symptoms and possible diagno-
ses from the internet and would discuss about it with the doctors. Both 
his father and brother were under psychiatric treatment with a diagnosis 
of schizophrenia and obsessive-compulsive disorder, respectively. The 
patient was diagnosed as panic disorder. He was treated with escitalo-
pram and alprazolam which were titrated up to 15 mg nocte and 0.5 mg 
tds respectively. 
After 3 months of treatment, he continued to have frequent and 
severe panic attacks at 1 to 3 episodes per day for almost every day 
resulting in very frequent visits to the emergency department. The 
patient slept around the hospital compound to ease him getting the med-
ical attention whenever panic attack occurred. In addition, he stated that 
he was likely to become sexually aroused during sleep at home which 
he attributed to jin. He postponed his study incapacitated by the severe 
anxiety and low mood. Differential diagnosis of major depressive disor-
der was considered at this stage. In view that the patient was also at high 
risk for schizophrenia, quetiapine XR 50 mg nocte was started to aug-
ment the escitalopram3,4). His condition improved resulting in less fre-
quent visits to the emergency department. The compliance to treatment, 
however, was not very good.
Seventeen months after the initial presentation, he described hearing 
voices of people talking about him and reciting verses from the Quran at 
night for the first time. The quetiapine XR was increased to 100 mg 
nocte. Two weeks later, the voices became more prominent and com-
manded him to kill himself leading to two week admission in psychiat-
ric ward. Quetiapine XR was increased up to 500 mg nocte. His diagno-
sis was revised to schizophrenia. After 2 months, he experienced mini-
mal anxiety, depressive and psychotic symptoms. He went to work in 
Kuala Lumpur for about 6 months. However, the symptoms recurred 
after his default of treatment for which quetiapine XR 500 mg was 
restarted and his condition had improved since then.
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DISCUSSION
The recognition that high risk subjects for schizophrenia are charac-
terized by high prevalence of anxiety and depressive disorders in addi-
tion to their attenuated psychotic symptoms1) is not new. The term and 
concept, pseudoneurotic schizophrenia, was proposed by Hoch and 
Polatin in 1949 to delineate a poorly defined subgroup of schizophrenia 
patients who presented with prominent anxiety symptoms, which 
masked the underlying basic mechanisms of schizophrenia5,6). The diag-
nostic term, however, is not part of current classification systems and 
thus has fallen out of clinical use. 
Pseudoneurotic schizophrenia is characterized by presence of pri-
mary clinical symptoms which was thought to reflect the basic symp-
toms of schizophrenia which operate even before the onset of psychotic 
symptoms. Significantly, this patient had low mood and unusual sexual 
arousal suggesting an altered sensorimotor-autonomic integration in 
psychosexual functioning5). Clinical presentations are often dominated 
by the secondary clinical symptoms, many of which can be recognized 
as developments of various primary symptoms, or combinations of such 
symptoms. The term pan-anxiety is used to designate diffuse anxiety, 
the presence of which is marked by special intensity, duration and per-
vasiveness. The intensity may vary from vague disquietude to panic, but 
the subjective experience of anxiety is almost constantly present and is 
frequently dominating6). This patient showed, in contrast to the usual 
neurotic patients, an all-pervading anxiety in which everything that the 
patient experienced influenced this anxiety. Pan-anxiety was always 
manifested no matter how he tried to break through the conflict or to 
avoid it.
The anxiety symptoms in this patient did not remit with adequate 
dose of selective serotonin reuptake inhibitor and benzodiazepine. 
Quetiapine XR was added but at a low dose 50 mg nocte. It was chosen 
for its low risk of extrapyramidal side effect. A recent study suggests 
quetiapine has acute anxiolytic effects for patients with specific pho-
bia3). In another study, quetiapine XR (50-300 mg/day) monotherapy is 
effective in the short term in improving symptoms of anxiety in older 
patients with GAD, with symptom improvement seen as early as week 
14). Currently, it is an approved adjunctive treatment for patients with 
major depressive disorder7). The dose of quetiapine remained at low 
dose 50 mg nocte for more than a year before the emergence of psycho-
sis.
Most clinicians still hesitate to prescribe antipsychotic treatment 
due to ethical consideration such as false-positive identification of pro-
dromal phase. Additionally, antipsychotics are often associated with 
adverse effects that are undesirable for young people, such as pro-
nounced weight gain8) making this option less attractive compared to 
other available psychological and pharmacological intervention9) even 
though randomized controlled studies have demonstrated the effective-
ness of antipsychotics such as risperidone10,11), olanzapine12) and ami-
sulpiride13) in reducing the conversion rate to schizophrenia. In an 
open-label study, aripiprazole shows a promising efficacy and safety 
profile for the psychosis prodrom14). 
CONCLUSION
Anxiety symptoms can be very prominent and may not respond ade-
quately to the standard antidepressant and anxiolytic treatment during 
the prodromal phase of schizophrenia. Quetiapine is an interesting treat-
ment option for patients at high risk for schizophrenia with prominent 
anxiety and/or depressive symptoms for the following reason: 1) it is 
atypical antipsychotics with low risk of extrapyramidal side effects; 2) it 
is already approved as adjunctive treatment for major depressive disor-
der; 3) it shows promising efficacy for generalized anxiety disorder.
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